Senior/Research Associate, Functional Genomics at NewLimit

South San Francisco, California, United States

NewLimit Logo
Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

  • Bachelor’s degree in cell biology, molecular biology, or a related natural science or industry experience
  • 2+ years of work experience in a cell or molecular biology laboratory (academic or industry)
  • Experience with molecular cloning, nucleic acid analysis (RT-qPCR, gel electrophoresis), and related molecular biology methods
  • Experience with mammalian cell culture

Responsibilities

  • Collaborate with our Single Cell Technology team to implement large-scale, single cell perturbation experiments with custom chemistries
  • Build recombinant DNA vectors by synthesis and cloning to enable large-scale single cell perturbation experiments
  • Prepare, titer, and apply viral vectors (lentiviral, AAV) to transduce mammalian cell lines and primary cells
  • Contribute to scaling and improving pooled single cell perturbation screens

Skills

molecular cloning
RT-qPCR
gel electrophoresis
mammalian cell culture
lentiviral vectors
AAV
FACS
flow cytometry
Python
Unix
next-generation sequencing
single cell genomics
pooled perturbation screening

NewLimit

Medicines for healthspan extension via epigenetics

About NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

South San Francisco, CaliforniaHeadquarters
2022Year Founded
$38.9MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Unlimited Paid Time Off

Risks

Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.
Ethical concerns and regulatory scrutiny may delay product approvals.
Competition from similar biotech firms could impact NewLimit's market share.

Differentiation

NewLimit focuses on epigenetic reprogramming to extend human healthspan.
The company uses single-cell genomics and machine learning for drug discovery.
NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Upsides

Increased interest in epigenetic reprogramming boosts NewLimit's market potential.
Machine learning aids in identifying novel drug candidates for age-related diseases.
FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

Land your dream remote job 3x faster with AI